Neuronetics Launches Innovations To NeuroStar Advanced Therapy’s Proprietary TrakStar Platform
Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,
Short Volatility Alert: Neuronetics, Inc.
On Thursday, shares of Neuronetics, Inc. (NASDAQ: STIM) experienced volatile short activity. After the activity, the stock price went up +0.76% to $2.65.
The overall sentiment for STIM has been Bearish.
Despite Competition This Analyst Finds BrainsWay Attractive
Yesterday BrainsWay Ltd (NASDAQ:BWAY) reported Q2 sales of $8.0 million, up 14% Y/Y, missing the consensus of $8.47 million, amid a…
Recap: Neuronetics Q2 Earnings
Neuronetics (NASDAQ:STIM) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Neuronetics Q2 EPS $(0.39) Beats $(0.41) Estimate, Sales $16.30M Beat $15.46M Estimate
Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.41) by 4.88 percent. This is a 34.48 percent decrease over losses of $(0.29) per share from the
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.